Navigation Links
Transgenomic Reports Second Quarter Financial Results
Date:8/11/2011

arter in 2010. Within this business our pharmacogenomics research services grew 223% to $1.0 million for the second quarter of 2011. We expect to continue seeing strong performance in this segment," commented Craig Tuttle, President and Chief Executive Officer for the company. "Testing volume and revenues increased in both our Neurology lab business and in our FAMILION product group with sales of $1.2 million for Neurology and $2.6 million for FAMILION. We expect these lab areas to continue growing due to new test offerings and further sales penetration into their respective markets. The FAMILION tests are an important means of identifying cardiac channelopathies, potentially life threatening defects in the heart.  Both doctors and patients recognize the benefit that these tests provide in at risk populations, and we expect to continue to expand this franchise."

"As we experienced in the first quarter, and again this quarter, our significant stock price increase has resulted in non-cash charges due to the revaluation of our preferred stock conversion feature and warrant liability," Tuttle continued. "In the first quarter, this resulted in an expense of $2 million and, with further strengthening of our share price in second quarter; the expense reached an additional $4.2 million bringing the total expense for the first six months of 2011 to $6.3 million. While this non-cash expense appears significant, I want to emphasize that it does not affect our cash flow.  I trust that shareholders are encouraged by the growth in our market capitalization since we secured this financing and acquired the FAMILION Business."

Modified EBITDA, which we are emphasizing as an appropriate and sound measure of our real business results, improved to $(369,000) in the second quarter of 2011 from $(939,000) in the second quarter of 2010.

Transgenomic anticipates growth in both our diagnostics and our laboratory services businesses as we commercialize new assa
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011
2. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
3. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
4. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
5. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
6. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
7. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
8. Transgenomic Reports Third Quarter Financial Results
9. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
10. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Licensing Opportunities , , ... KANSAS CITY, Mo. , May 17 ... Inc., today announced that it is continuing its strategic international expansion ... group of leading research hospitals and institutes based in Toronto, ...
... , May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... orphan medicinal product designation from the Committee for Orphan ... its compound AEZS-108 for the treatment of ovarian cancer. ...
... China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic Acid ... financial results of the first quarter ended March,31, 2010 ... increased 66.0% to $12.4 million, -- Q1 ...
Cached Biology Technology:The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
(Date:4/22/2014)... HOUSTON (April 22, 2014) Biotechnology scientists must ... for new patent and licensing guidelines, according to a ... Policy. , Published in the current issue of the ... on the June 2013 U.S. Supreme Court ruling in ... Genetics that naturally occurring genes are unpatentable. The court ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... adults with the blood cancer mixed-lineage leukemia (MLL) typically have ... birthdays. Although there are varying causes of MLL, most cases ... and the AF4 genes. When the ... cancer-causing oncogene is created. Although researchers have known that the ...
... engineering holds great promise for the treatment of conditions ... injuries. However, bone and cartilage currently produced in ... the body so they,re not clinically viable. Dr. ... of Medicine & Dentistry at The University of Western ...
... 2008 -- A rat thought extinct for 11 million years ... new species discovered in the Greater Mekong Region of Southeast ... launched by World Wildlife Fund (WWF). First ... discovered or newly identified by science between 1997 and 2007 ...
Cached Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Building better bones and tissue in the lab 2Over 1,000 species discovered in the Greater Mekong in past decade 2
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Novexin offers bespoke, cost-effective solutions for complex protein ... extensive expertise and experience to help you develop a ... , , ... , transfer all methodology ...
... is a chemiluminescent signal enhancing reagent ... boost the signal obtained with all ... ChemiLucent™ Plus is derived from a ... complex- or chemiluminescent substrate enhancers, ChemiLucent™ ...
... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
Biology Products: